GSTM1 and chronic kidney disease: By using the above study design and analysis method, this study demonstrated that initiation of ESA therapy when Hb levels decreased below 11 g/dL could reduce the risk of renal events in non-dialysis CKD patients with anemia more effectively than initiation of ESA therapy at below 9 g/dL.